| Rosiglitazone prevents diabetes by increasing beta-cell mass in an animal model of type 2 diabetes characterized by reduced beta-cell mass at birth. | |
| | |
MedLine Citation:
|
PMID: 17970760 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
AIM: Interventions that preserve or increase beta-cell mass may also prevent type 2 diabetes. Rosiglitazone prevents diabetes in people with high glucose levels who have impaired glucose tolerance and/or impaired fasting glucose. The effect of this drug on both glucose levels and beta-cell mass was studied in a rat model of diabetes, characterized by reduced beta-cell mass at birth with normoglycaemia, and progression to dysglycaemia with age. METHODS: Female Wistar rats were given either saline (vehicle) or nicotine during pregnancy and lactation. Offspring of saline-exposed dams were given vehicle and offspring of nicotine-exposed dams were randomized to receive either vehicle or rosiglitazone starting at weaning. Beta-cell mass, proliferation and apoptosis were determined at birth and at 4 and 26 weeks of age. Glucose homeostasis was examined following sequential oral glucose tolerance tests (OGTT). RESULTS: Rosiglitazone treatment prevented the development of dysglycaemia in nicotine-exposed animals. The ability of rosiglitazone to preserve normoglycaemia appeared to be because of its ability to increase beta-cell mass through a combination of enhanced beta-cell proliferation and decreased beta-cell apoptosis. CONCLUSIONS: These results suggest that if rosiglitazone administration is started prior to the onset of glucometabolic abnormalities, it prevents the onset of dysglycaemia by partially restoring beta-cell mass in animals with reduced beta-cell mass at birth. |
| | |
Authors:
|
A C Holloway; J J Petrik; J E Bruin; H C Gerstein |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't Date: 2007-10-26 |
Journal Detail:
|
Title: Diabetes, obesity & metabolism Volume: 10 ISSN: 1463-1326 ISO Abbreviation: Diabetes Obes Metab Publication Date: 2008 Sep |
Date Detail:
|
Created Date: 2008-10-21 Completed Date: 2009-05-14 Revised Date: 2009-11-03 |
Medline Journal Info:
|
Nlm Unique ID: 100883645 Medline TA: Diabetes Obes Metab Country: England |
Other Details:
|
Languages: eng Pagination: 763-71 Citation Subset: IM |
Affiliation:
|
Reproductive Biology Division, Department of Obstetrics and Gynecology, McMaster University, Hamilton, Ontario, Canada. hollow@mcmaster.ca |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Animals, Newborn Apoptosis Cell Count Diabetes Mellitus, Type 2 / prevention & control* Female Glucose Intolerance / chemically induced, drug therapy*, metabolism Hypoglycemic Agents / pharmacology* Insulin-Secreting Cells / cytology, drug effects*, metabolism Male Nicotine Nicotinic Agonists Pregnancy Random Allocation Rats Rats, Wistar Thiazolidinediones / pharmacology* |
| Chemical | |
Reg. No./Substance:
|
0/Hypoglycemic Agents; 0/Nicotinic Agonists; 0/Thiazolidinediones; 122320-73-4/rosiglitazone; 54-11-5/Nicotine |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Effects of combined PPARgamma and PPARalpha agonist therapy on reverse cholesterol transport in the ...
Next Document: Acute effect of metformin on exercise capacity in active males.